Vangatalcite | CAS# 12539-23-0

MedKoo Cat#: 413656 | Name: Vangatalcite

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vangatalcite is a biochemical

Chemical Structure

Vangatalcite

CAS#12539-23-0

Theoretical Analysis

MedKoo Cat#: 413656

Name: Vangatalcite

CAS#: 12539-23-0

Chemical Formula: CH18Al2Mg4O18

Exact Mass: 467.9526

Molecular Weight: 469.32

Elemental Analysis: C, 2.56; H, 3.87; Al, 11.50; Mg, 20.72; O, 61.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Vangatalcite; MA20; MA 20; MA-20

IUPAC/Chemical Name

dialuminum(III) tetramagnesium carbonate dodecahydroxide trihydrate

InChi Key

HITXWGXAPHJXHJ-UHFFFAOYSA-A

InChi Code

InChI=1S/CH2O3.2Al.4Mg.15H2O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;15*1H2/q;2*+3;4*+2;;;;;;;;;;;;;;;/p-14

SMILES Code

[O-]C([O-])=O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 469.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Borm KJ, Oechsner M, Düsberg M, Buschner G, Weber W, Combs SE, Duma MN. Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. Radiother Oncol. 2020 Jan;142:195-201. doi: 10.1016/j.radonc.2019.08.021. Epub 2019 Sep 17. PMID: 31540747. 2: Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340. PMID: 26200977; PMCID: PMC4556358. 3: Gross JP, Whelan TJ, Parulekar WR, Chen BE, Rademaker AW, Helenowski IB, Donnelly ED, Strauss JB. Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):165-173. doi: 10.1016/j.ijrobp.2019.05.002. Epub 2019 May 11. PMID: 31085285. 4: Bornheim S, Croisier JL, Maquet P, Kaux JF. Transcranial direct current stimulation associated with physical-therapy in acute stroke patients - A randomized, triple blind, sham-controlled study. Brain Stimul. 2020 Mar- Apr;13(2):329-336. doi: 10.1016/j.brs.2019.10.019. Epub 2019 Oct 31. PMID: 31735645. 5: de Jel DVC, Hol JA, Ooms AHAG, de Krijger RR, Jongmans MCJ, Littooij AS, Drost J, van Grotel M, van den Heuvel-Eibrink MM. Paediatric metanephric tumours: a clinicopathological and molecular characterisation. Crit Rev Oncol Hematol. 2020 Jun;150:102970. doi: 10.1016/j.critrevonc.2020.102970. Epub 2020 Apr 24. PMID: 32371339. 6: Bershad AK, Mayo LM, Van Hedger K, McGlone F, Walker SC, de Wit H. Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacology. 2019 Sep;44(10):1698-1705. doi: 10.1038/s41386-019-0402-z. Epub 2019 Apr 30. PMID: 31042696; PMCID: PMC6785008. 7: Bashir S, Al-Hussain F, Hamza A, Asim Niaz T, Albaradie R, Habib SS. Cognitive function assessment during 2 mA transcranial direct current stimulation in DLPFC in healthy volunteers. Physiol Rep. 2019 Oct;7(20):e14264. doi: 10.14814/phy2.14264. PMID: 31660693; PMCID: PMC6817993. 8: Lui GK, McGarry C, Bhatt A, Book W, Riehle-Colarusso TJ, Dunn JE, Glidewell J, Gurvitz M, Hoffman T, Hogue CJ, Hsu D, Obenhaus S, Raskind-Hood C, Rodriguez FH 3rd, Zaidi A, Van Zutphen AR. Surveillance of Congenital Heart Defects among Adolescents at Three U.S. Sites. Am J Cardiol. 2019 Jul 1;124(1):137-143. doi: 10.1016/j.amjcard.2019.03.044. Epub 2019 Apr 10. PMID: 31030970. 9: Dobbs B, Pawlak N, Biagioni M, Agarwal S, Shaw M, Pilloni G, Bikson M, Datta A, Charvet L. Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson's disease. J Neuroeng Rehabil. 2018 Dec 7;15(1):114. doi: 10.1186/s12984-018-0457-9. PMID: 30522497; PMCID: PMC6284269. 10: Ortiz C, Rondeau NU, Moore LE, Mulla ZD. Parental Age and the Risk of Gestational Hypertension and Preeclampsia. South Med J. 2018 Sep;111(9):544-548. doi: 10.14423/SMJ.0000000000000854. PMID: 30180252.